ProSAAS (Proprotein convertase subtilisin/kexin type 1 inhibitor) (Proprotein convertase 1 inhibitor) (pro-SAAS) [Cleaved into: KEP; Big SAAS (b-SAAS); Little SAAS (l-SAAS) (N-proSAAS); Big PEN-LEN (b-PEN-LEN) (SAAS CT(1-49)); PEN; Little LEN (l-LEN); Big LEN (b-LEN) (SAAS CT(25-40))]
1_MAGSP 6_ LLWGP 11_ RAGGV 16_ GLLVL 21_ LLLGL 26_ FRPPP 31_ ALCAR 36_ PVKEP 41_ RGLSA 46_ ASPPL 51_ AETGA 56_ PRRFR 61_ RSVPR 66_ GEAAG 71_ AVQEL 76_ ARALA 81_ HLLEA 86_ ERQER 91_ ARAEA 96_ QEAED 101_ QQARV 106_ LAQLL 111_ RVWGA 116_ PRNSD 121_ PALGL 126_ DDDPD 131_ APAAQ 136_ LARAL 141_ LRARL 146_ DPAAL 151_ AAQLV 156_ PAPVP 161_ AAALR 166_ PRPPV 171_ YDDGP 176_ AGPDA 181_ EEAGD 186_ ETPDV 191_ DPELL 196_ RYLLG 201_ RILAG 206_ SADSE 211_ GVAAP 216_ RRLRR 221_ AADHD 226_ VGSEL 231_ PPEGV 236_ LGALL 241_ RVKRL 246_ ETPAP 251_QVPAR
1: May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity (By similarity)
2: Endogenous ligand for GPR171. Neuropeptide involved in the regulation of feeding
3: Endogenous ligand for GPR171. Neuropeptide involved in the regulation of feeding